| Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease Supernus Pharmaceuticals, Inc. announced that the FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).“Continuous subcutaneous apomorphine infusion already has a proven and established 30-year history in Europe, where it has helped deliver more consistent control of motor fluctuations for thousands of patients,” said Rajesh Pahwa, M.D., Laverne and Joyce Rider Professor of Neurology at the University of Kansas School of Medicine, Director of the Movement Disorder Program at The University of Kansas Health System, and a clinical trial investigator for ONAPGO. Read The Official Press Release “Hope is strong after this approval, the third in less than a year. Combined with momentum from the National Plan to End Parkinson’s Act being signed into law, 2025 has the potential to be a banner year for people living with Parkinson’s and the healthcare providers caring for them.” — Andréa Merriam Crespo, CEO “The therapy’s approval was based on data from the TOLEDO study (NCT02006121), a randomized, double-blind study in which treatment with the device was associated with a difference of –1.89 hours per day of OFF time for patients with PD in comparison with placebo. Published in the Lancet Neurology in 2018, the study randomly assigned 106 patients living with the disease to either 3-mg/hour to 8-mg/hour dose of apomorphine (n = 53) or placebo saline infusion (n = 53) during their wake hours for a 12-week period.” – Marco Meglio & Isabella Ciccone, MPH Read The Full Neurology Live Article |
The Beaufort Area Parkinson’s Support Group 
Leave a comment